DALLAS and NEW YORK, Oct. 11 /PRNewswire-FirstCall/ — Access Pharmaceuticals,
Inc. (OTC Bulletin Board:
ACCP), a biopharmaceutical company specializing in products for
cancer and supportive care, announced the highlights from a poster
presentation on European clinical experience of MuGard at this
year’s European Society of Medical Oncology Conference in Milan,
Italy. Some of the findings reported in the ESMO presentation
included:
MuGard provided a significant improvement and/or stabilization of
oral mucositis lesions and symptoms of oral mucositis (OM) in more
than 75% of cancer patients treated with radiotherapy/chemotherapy;
Patients reported a 52% significant reduction in oral discomfort
(oral pain and swallowing ability) in patients with pre-existing
lesions of OM, and reported a substantial reduction in the use of
pain medication; MuGard has a ready-to-use formulation that is well
accepted by 86% of patients, as reported in this assessment
program; No MuGard-related adverse reactions have been identified
in clinical practice; MuGard represents a valuable therapeutic
option in the treatment and prevention of OM in cancer patients
undergoing radio/chemotherapy.
“These additional findings out of Europe are very exciting and
strengthen our belief in the clinical benefits that MuGard can
provide patients undergoing radiation and chemotherapy,” said
Jeffrey Davis, CEO of Access Pharmaceuticals. He continued,
“This data confirms the competitive advantages of MuGard over the
current treatment options on the market and we will use this data
to educate patients, clinicians and the medical industry on the
superior attributes of our product.”
Earlier this year, Access presented MuGard data and clinical
experience at the MASCC Conference (Multinational Association of
Supportiv
‘/>”/>
